ReviewNature reviews. Endocrinology2010
Pharmacological management of appetite expression in obesity.
Review in Nature reviews. Endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Bioactive Exploration in Functional Foods: Unlocking Nature's Treasures.Current pharmaceutical biotechnology · 2024Pooled it
- Pooled it
- Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016Pooled it
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.Drug design, development and therapy · 2014Pooled it
- Effect of DHA supplementation in a very low-calorie ketogenic diet in the treatment of obesity: a randomized clinical trial.Endocrine · 2016Trial
- Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity.Endocrine · 2014Trial
- Atlas of GLP-1 expression in the mouse brain: Neuroanatomical basis for metabolic and psychiatric effects.Brain medicine : from neurons to behavior and better health · 2026Article
- Effects of Livergol and Hydroalcoholic Extracts of Barberry, Jujube, and Flixweed on Oxidative Stress and Inflammatory Gene Expression in a MASLD Animal Model.Mediators of inflammation · 2026Article
- Central pramlintide administration potently suppresses operant responding for sucrose and locomotor activity in male rats.Physiology & behavior · 2025Article
- A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment.Science advances · 2024Article
- Anti-obesity activity of human gut microbiota Bacteroides stercoris KGMB02265.Archives of microbiology · 2023Article
- Nutritional supplements improve cardiovascular risk factors in overweight and obese patients: A Bayesian network meta-analysis.Frontiers in nutrition · 2023Article
- The anorexic effect of DL-fenfluramine is dependent on animals' habituation to different food types.Frontiers in integrative neuroscience · 2022Article
- Reciprocal modulation of 5-HT and octopamine regulates pumping via feedforward and feedback circuits inProceedings of the National Academy of Sciences of the United States of America · 2019Article
- How does lorcaserin facilitate weight loss and who will benefit?Nature reviews. Endocrinology · 2018Article
- Hepatic lesions induced by feeding Western diets to Zucker fatty rats, an insulin-resistant model.Journal of toxicologic pathology · 2018Article
- Sympathetic inputs regulate adaptive thermogenesis in brown adipose tissue through cAMP-Salt inducible kinase axis.Scientific reports · 2018Article
- Pharmacological interventions for obesity: current and future targets.Current addiction reports · 2018Article
- Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.Biological psychiatry · 2017Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For obese individuals, successful weight loss and maintenance are notoriously difficult. Traditional drug development fails to exploit knowledge of the psychological factors that crucially influence appetite, concentrating instead on restrictive criteria of intake and weight reduction, allied to a mechanistic view of energy regulation. Drugs are under development that may produce beneficial changes in appetite expression in the obese. These currently include glucagon-like peptide-1 analogs such as liraglutide, an amylin analog davalintide, the 5-HT(2C) receptor agonist lorcaserin, the monoamine re-uptake inhibitor tesofensine, and a number of combination therapies such as pramlintide and metreleptin, bupropion and naltrexone, phentermine and topiramate, and bupropion and zonisamide. However, the effects of these treatments on eating behavior remain poorly characterized. Obesity is typically a consequence of overconsumption driven by an individual's natural sensitivity to food stimuli and the pleasure derived from eating. Intuitively, these processes should be effective targets for pharmacotherapy, and behavioral analysis can identify drugs that selectively affect desire to eat, enjoyment of eating, satiation or postmeal satiety. Rational interventions designed specifically to modulate these processes could limit the normally aversive consequences of caloric restriction and maximize an individual's capacity to successfully gain control over their appetite.
Indexed as
Identifiers
20234354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.